A comparative study of the preventive use of tilmicosin phosphate (Pulmotil premix) and Mycoplasma hyopneumoniae vaccination in a pig herd with chronic respiratory disease.
This study was conducted to compare the effects of a preventive in-feed medication programme using tilmicosin (Pulmotil 200 premix, Elanco Animal Health) at 200 p.p.m. with those of Mycoplasma hyopneumoniae (Mh) vaccination programme (Stellamune Mycoplasma, Pfizer Animal Health). A pig herd with chronic respiratory disease in which infection with Mh played an important role was selected, and a total of 204 piglets were randomly allocated to either the medication (P) or the vaccination (V) group. Pigs in the P group received medicated feed for 3 weeks after weaning (days 34-55), and for 2 weeks late in the nursery period (days 77-98). The piglets in the V group were vaccinated twice intramuscularly, at 4 and 22 days of age. The two groups were compared on the basis of average daily gain (ADG), feed conversion rate (FCR), additional curative medication days (CMD), overall mortality (major variables), a coughing index, pneumonia lesions, and serology against Mh, influenza H1N1 and influenza H3N2 viruses, Actinobacillus pleuropneumoniae (App) and porcine reproductive and respirator, syndrome virus (PRRSV) (minor variables). No significant differences (P > 0.05) were observed for ADG (555 g/day in P group; 567 g/day in V group), FCR (2.64 in P group; 2.41 in V group) and mortality rate (11% in P group; 7% in V group). The average number of additional curative medication days (CMD) per pig was significantly higher (P < 0.01) in the P group (1.5) than in the V group (0.58). At slaughter age, the serological results and the prevalence of macroscopic lung lesions were comparable in the two groups (P > 0.05). With the exception of CMD, the preventive use of tilmicosin at this swine farm was found to confer similar beneficial effects to Mh vaccination.
Mateusen
B
B
Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, Belgium. bart.mateusen@rug.ac.be
Maes
D
D
Hoflack
G
G
Verdonck
M
M
de Kruif
A
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology; D018942:Macrolides; D009174:Mycoplasma / Q000276:immunology*; D009175:Mycoplasma Infections / Q000517:prevention & control / Q000662:veterinary*; D012140:Respiratory Tract Diseases / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D016896:Treatment Outcome; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014611:Vaccination / Q000662:veterinary
D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; D018942:Macrolides; C052319:tilmicosin; D015645:Tylosin